ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Objections Delay GAO Report On Cancer Control

March 7, 1980

Dept. of Defense opens program announcements for prostate cancer research.

December 10, 2004

Duke Vice Dean Cuffe Promises Complete, Independent Probe Of Work By Potti, Nevins.

July 30, 2010

California Land Control Grant, Need Administrator

April 21, 1978

Klausner To Revamp NCI Budget Process To Make Categories Mean What They Say

December 8, 1995

Study Finds Gene Expression Test Predicts Stage I or II Recurrence

August 30, 2013